SR9009, also known as Stenabolic, is a research drug developed by professor Thomas Burris of the Scripps Research Institute that has been linked to fat-loss and increased workout endurance. Unlike traditional SARMs which bind to androgen receptors, Stenabolic has been shown to be a PPAR alpha modifier similar to Cardarine - which works by binding the Rev-ErbA protein which influences lipid and glucose metabolism also while increasing mitochondria within cells. Mice given SR9009 were able to run 50% longer than non-treated mice, has been linked to anti-tumor effects in small cell lung cancer, and has shown no suppression side-effects.
All our SARM's are laboratory tested and we publish the certificates of analysis to ensure our product quality. We have strict standards for the specifications of our products and they are not released to the public without meeting these specs. The Certificates of Analysis are available on the bottom of each SARM page for the lot of available of that product.
These SARMs are in a PEG (Polyethylene Glycol Solution) please inquire about any allergies.
20mg (1.0mL) per day
It is recommended to add the SARMs into juice or a shake directly with dropper when administering doses.
Available in 30mL, 60mL, 90mL, or 120mL amounts
A typical cycle lasts 5-8 weeks
A Post-Cycle Therapy is not needed with Stenabolic as it is not hormonally based nor suppressive and does not aromatize.
Disclaimer: SARMs Rx products are furnished for LABORATORY RESEARCH USE ONLY. This product should only be handled by qualified, and licensed professionals. The product may not be used as a drug, agricultural or pesticidal product, food additive or household chemical – and may not be misbranded as such. All information on this website is available for educational purposes only. Bodily introduction of any kind into humans and/or animals is strictly forbidden by law.
SR9009 has shown experimental benefits associated with the following:
SR9009 has not shown any suppressive effect has it is not hormonal based. It is also not associated with testosterone so this eliminates the chances of aromatization to estrogen, liver, kidney, or prostate danger
Selective-Androgen-Receptor-Modulators are just that, they selectively bind androgen receptors. The idea behind these compounds are great; create a compound that binds androgen receptors on only muscle tissue and nowhere else. One of the biggest problems with androgens are the negative side effects from the androgen binding receptors in different places on the body such as your prostate or liver which can cause overgrowth or even increase the chance of cancer. So, SARMs are attempting to negate that by being compounds that only bind androgen receptors on muscle tissue (that's the Selective part)- you get growth in your muscle but not in other organs.
These are experimental compounds which have not been deemed approved for consumption, but they are avaialble for research purpose. Take a look at the science listed to get an idea!
"Our study provided a novel viewpoint indicating that the REV-ERB agonist SR9009 could be a novel and promising therapeutic strategy in first- or second-line SCLC treatment. The anti-SCLC effect of SR9009 is mediated by REV-ERB dependent suppression of autophagy via direct repression of the autophagy gene Atg5."
Citation: Shen, W., Zhang, W., Ye, W., Wang, H., Zhang, Q., Shen, J., Hong, Q., Li, X., Wen, G., Wei, T., & Zhang, J. (2020). SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy. Theranostics, 10(10), 4466–4480. https://doi.org/10.7150/thno.42478
"Rev-erb-α-deficiency resulted in deactivation of the Stk11–Ampk–Sirt1–Ppargc1-α signaling pathway, whereas autophagy was up-regulated, resulting in both impaired mitochondrial biogenesis and increased clearance. Muscle over-expression or pharmacological activation of Rev-erb-α increased respiration and exercise capacity. This study identifies Rev-erb-α as a pharmacological target which improves muscle oxidative function by modulating gene networks controlling mitochondrial number and function."
Citation: Woldt, E., Sebti, Y., Solt, L. A., Duhem, C., Lancel, S., Eeckhoute, J., Hesselink, M. K., Paquet, C., Delhaye, S., Shin, Y., Kamenecka, T. M., Schaart, G., Lefebvre, P., Nevière, R., Burris, T. P., Schrauwen, P., Staels, B., & Duez, H. (2013). Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nature medicine, 19(8), 1039–1046. https://doi.org/10.1038/nm.3213
"Here, in gain- and loss-of function studies, we show that Rev-erb-α also controls muscle mass. Rev-erb-α-deficiency in skeletal muscle leads to increased expression of the atrophy-related genes (atrogenes), associated with reduced muscle mass and decreased fiber size. By contrast, in vivo and in vitro Rev-erb-α over-expression results in reduced atrogenes expression and increased fiber size. Finally, Rev-erb-α pharmacological activation blocks dexamethasone-induced upregulation of atrogenes and muscle atrophy. This study identifies Rev-erb-α as a promising pharmacological target to preserve muscle mass."
Citation: Mayeuf-Louchart, A., Thorel, Q., Delhaye, S., Beauchamp, J., Duhem, C., Danckaert, A., Lancel, S., Pourcet, B., Woldt, E., Boulinguiez, A., Ferri, L., Zecchin, M., Staels, B., Sebti, Y., & Duez, H. (2017). Rev-erb-α regulates atrophy-related genes to control skeletal muscle mass. Scientific reports, 7(1), 14383. https://doi.org/10.1038/s41598-017-14596-2
All of our SARMs are lab verified by an international third-party lab that tests and verifies product accuracy & purity by Liquid Chromatography & Mass Spectrometry with a minimum purity standard of 99% whose reports can be viewed below: